Here, we attempted to further characterize the observed association of FGF23 with hemoglobin in CKD by taking into account both cFGF23 and the biologically active iFGF23, as well as the biomarkers of iron metabolism, including hepcidin, and EPO levels. The gene discussed is EPO; the disease is chronic kidney disease.